Conference, BMS finally revealed early data for its Alzheimer’s disease psychosis trials of KarXT, marketed as Cobenfy in ...
Summit Therapeutics was warned twice by the FDA that the Phase 3 trial used to support the application for ivonescimab did ...
HARMONi-10 is a multi-regional, open-label, potentially registration-enabling Phase III clinical trial. The primary endpoint ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Thomas H. Glocer intends to retire ...
Biogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito ...
Randomized, double-masked, placebo-controlled U.S. study evaluates two doses of EO2002, an investigational cell therapy ...
SAN DIEGO, CA / ACCESS Newswire / November 18, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), ...
Laboratory results showed a strong neurite outgrowth in human motor neurons, advancing ExoPTEN toward treatments for ...
(NYSE: PFE) today announced that it entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology ...
Korean decision to grant extends reconstitution protection into another key Asia-Pacific market, reinforcing a multi-layered ...
The seventh symposium in Gangneung, South Korea, featured clinical research on REJURAN® polynucleotides and a ...
Pfizer is officially entering in vivo CAR T with China’s RNA-focused biotech Starna Therapeutics in a deal that could reach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results